HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy-Reference-Cited by-同舟云学术

HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy

Published:2018-02-14 Issue:4 Volume:7 Page:e1316438
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Nelde Annika¹²,Kowalewski Daniel J.¹³,Backert Linus¹⁴,Schuster Heiko¹³,Werner Jan-Ole²,Klein Reinhild²,Kohlbacher Oliver⁴⁵⁶,Kanz Lothar²,Salih Helmut R.²⁷,Rammensee Hans-Georg¹⁸,Stevanović Stefan¹⁸,Walz Juliane S.²

Affiliation:

1. Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany

2. Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany

3. Immatics Biotechnologies GmbH, Tübingen, Germany

4. Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tübingen, Tübingen, Germany

5. Quantitative Biology Center, University of Tübingen, Tübingen, Germany

6. Biomolecular Interactions, Max Planck Institute for Developmental Biology, Tübingen, Germany

7. Clinical Cooperation Unit Translational Immunology, German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany

8. German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany

Funder

European Union (EU)

Deutsche Forschungsgemeinschaft (DFG)

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2017.1316438

Reference60 articles.

1. Cancer Immunotherapy

2. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

3. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

4. Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

5. Combination Checkpoint Blockade — Taking Melanoma Immunotherapy to the Next Level

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification and relative abundance of naturally presented and cross-reactive influenza A virus MHC class I-restricted T cell epitopes;Emerging Microbes & Infections;2024-02-08

2. DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts;Nature Communications;2023-10-23

3. Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes;Immunity;2023-06

4. The impact of immunopeptidomics: From basic research to clinical implementation;Seminars in Immunology;2023-03

5. Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment;Blood Advances;2022-07-15